Share this article
Share this article
ALBANY, N.Y., April 28, 2021 /PRNewswire/ -- Sepsis is major causes of morbidity and mortality in critically ill patients. Over the years, the understanding of molecular pathobiology and immunology of sepsis has expanded remarkably over decades, paving way to new avenues in the sepsis treatment market. Adoption of risk mitigation therapeutic approaches, most notably with continuous renal replacement therapy (CRRT), has expanded the outlook of the market. The focus on reducing the risk of bleeding has brought advances in intermittent hemodialysis (IHD) for ICU patients, thereby paving way to better outcomes in the sepsis treatment market. Further, ongoing research on the diagnostic markers, reinforced by positive regulatory landscape, has enriched the value chain. A case in point is ML-based sepsis detection. The changing global epidemiological burden of sepsis undergoing constant changes is expected to shape the contours of the sepsis treatment market.